Centre introduces stricter penalties for fake data in drug applications

The Centre has strengthened India's drug regulatory framework by empowering licensing authorities to debar companies and applicants that submit fake or fabricated data in support of applications filed under the Drugs Rules, 1945, the Ministry of Health and Family Welfare said on Thursday.

The ministry said the new provisions have been notified through amendments to the Drugs Rules, 1945, with the aim of improving transparency, accountability and integrity in the country's drug approval process.

Under the amended rules, applicants found to have submitted fabricated or misleading data may face rejection of their applications or cancellation of existing licences. They may also be barred from submitting fresh applications to the concerned regulatory authority for a specified period.

The government said due process would be followed before such action is taken. This includes issuing a show-cause notice to the concerned applicant or company. The amended framework also provides an avenue for appeal against the regulatory action.

The ministry said scientific data submitted by applicants forms the basis for assessing the quality, safety and efficacy of medicines. Submission of false or fabricated data, it noted, can undermine the integrity of the regulatory process, raise concerns over drug quality and potentially pose serious risks to public health.

The amendment is intended to deter malpractice, strengthen accountability among applicants and ensure that regulatory approvals are based on reliable and scientifically valid evidence.

According to the government, the move is part of broader efforts to strengthen India's pharmaceutical regulatory framework in line with global best practices.

The new provisions are also expected to promote greater compliance among drug manufacturers and distributors while creating stronger deterrence against regulatory misconduct. The amendments form part of wider reforms aimed at improving oversight, encouraging ethical practices and ensuring appropriate penalties for violations in the pharmaceutical sector.